Emerging research indicates that nicotine drives brain metastases in lung cancer by impairing the innate immune response of key nervous system cells.
Nicotine itself isn't carcinogenic, but it's the primary driver of tobacco addiction, making it a staple in cessation aids like patches, gums, inhalers, and lozenges. While these products are effective for many, new evidence suggests they warrant caution in certain cases.
A study in the Journal of Experimental Medicine reveals nicotine may exacerbate lung cancer progression by facilitating its spread to the brain.
Up to 40% of lung cancer patients develop metastases, where tumor cells detach and invade distant organs. Shockingly, about 90% of lung cancer fatalities stem from these secondary tumors, with brain metastases being among the most prevalent.
While smoking's link to lung cancer is well-established, its specific role in brain metastasis was unclear until now. Researchers at Wake Forest School of Medicine analyzed records from 281 lung cancer patients and found brain metastases far more common in smokers.
Given nicotine's ability to cross the blood-brain barrier, the team hypothesized its direct involvement. Testing this in genetically engineered mice prone to lung cancer, they observed that nicotine exposure significantly increased brain tumor development.
Further analysis showed nicotine binds to receptors on microglia—the central nervous system's resident immune cells in the brain, spinal cord, and retina.
Normally, microglia in their M1 state attack tumors. But nicotine shifts them to the tumor-promoting M2 state, suppressing immune defenses and enabling cancer growth. This mechanism explains nicotine's promotion of lung-to-brain metastasis.
Encouragingly, the compound parthenolide—derived from feverfew (Tanacetum parthenium)—blocks this M2 shift, potentially curbing metastasis risk.
Conducted in mouse models, this Wake Forest-led research paves the way for human trials to develop treatments preventing brain metastases.
Source
